Literature DB >> 8190200

How many people in the world have multiple sclerosis?

G Dean.   

Abstract

Entities:  

Mesh:

Year:  1994        PMID: 8190200     DOI: 10.1159/000110351

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


× No keyword cloud information.
  16 in total

1.  COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis.

Authors:  Gladson Muthian; Himanshu P Raikwar; Caroline Johnson; Johnson Rajasingh; Amit Kalgutkar; Lawrence J Marnett; John J Bright
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

2.  The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment.

Authors:  E L J Hoogervorst; P de Jonge; B Jelles; F J Huyse; I Heeres; H M van der Ploeg; B M J Uitdehaag; C H Polman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

3.  Molecular analysis of interleukin-25 exons 1 and 2 and its serum levels in Iranian patients with multiple sclerosis.

Authors:  Mohammad-Reza Javan; Narges Seyfizadeh; Saeed Aslani; Mehdi Farhoodi; Zohreh Babaloo
Journal:  Am J Clin Exp Immunol       Date:  2014-08-15

4.  Mortality trend for multiple sclerosis in Italy (1974-1993).

Authors:  T Tassinari; S Parodi; R Badino; M Vercelli
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

5.  The economic cost of multiple sclerosis in Sweden in 1994.

Authors:  F Henriksson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

6.  Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte.

Authors:  Gladson Muthian; John J Bright
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

Review 7.  The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.

Authors:  Ceri J Phillips
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Modifiable comorbidities and disability in multiple sclerosis.

Authors:  Shannon Overs; Christina M Hughes; Jodie K Haselkorn; Aaron P Turner
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

9.  The prevalence of multiple sclerosis in 3 US communities.

Authors:  Curtis W Noonan; Dhelia M Williamson; Judy P Henry; Robert Indian; Sharon G Lynch; John S Neuberger; Randolph Schiffer; Janine Trottier; Laurie Wagner; Ruth Ann Marrie
Journal:  Prev Chronic Dis       Date:  2009-12-15       Impact factor: 2.830

10.  Burden of disease of multiple sclerosis in Korea.

Authors:  Soo-Eun Chung; Hae-Kwan Cheong; Jae-Hyun Park; Ho Jin Kim
Journal:  Epidemiol Health       Date:  2012-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.